ClearPoint Neuro (NASDAQ:CLPT) shares rallied sharply on Wednesday, climbing roughly 50% after UniQure (NASDAQ:QURE) said the U.S. Food and Drug Administration indicated that data from a three-year analysis of its Phase I/II study could be used as the primary basis for a Biologics License Application (BLA) aimed at accelerated approval for AMT-130 in Huntington's disease.
AMT-130, UniQure’s investigational therapy for Huntington’s disease, is delivered using ClearPoint’s stereotactic navigation system together with the company’s SmartFlow cannula, linking the developer and the device maker in the program’s clinical pathway.
UniQure reported that during a recent Type B meeting the FDA communicated that the three-year analysis from the Phase I/II study would be acceptable as the primary basis of a BLA for accelerated approval. The company said it intends to submit the BLA in the third quarter of 2026.
The FDA has requested alignment on the design of the confirmatory study prior to the BLA submission. Part of that discussion includes consideration of using a concurrent control on standard-of-care therapy rather than a sham procedure. UniQure said the agency communicated it would work as expeditiously as possible on this effort.
Regulatory designations granted to AMT-130 were reiterated in UniQure’s announcement: the therapy holds Regenerative Medicine Advanced Therapy, Breakthrough Therapy, and Fast Track designations from the FDA. UniQure noted that the RMAT designation for AMT-130 is the first such designation for Huntington’s disease.
UniQure expects to receive the final minutes from the recent Type B meeting within 30 days. The company said it is committed to conducting the required confirmatory study without delay and expects to further align with the FDA on the study details prior to submitting the BLA.
Sectors affected - The developments touch biopharmaceutical developers and medical device makers involved in neurosurgical delivery systems, with secondary relevance to equity markets that trade shares of small-cap biotech and medtech firms.
Context and next steps - UniQure plans a BLA filing in Q3 2026 based on the three-year Phase I/II analysis, while formalizing the confirmatory study design in coordination with the FDA before submission. ClearPoint Neuro’s commercial products are directly used in administering AMT-130.
Market reaction - The immediate market response was a sharp uptick in ClearPoint Neuro’s stock price following UniQure’s announcement of the FDA discussion.